Evotec Expands Sanofi Link With Exclusive Stem Cell Diabetes Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Evotec’s deal with the French drugmaker to develop stem cell-based treatments for diabetes takes on even more importance following the demise of the biotech’s two lead proprietary candidate therapies.
You may also be interested in...
Deal Watch: Biogen Picks Up S1P Modulator To Try Competing With Novartis, Celgene
Weeks after immuno-oncology tie-up with Sanofi, Evotec signs a collaboration in fibrotic disease with Pfizer. Epirus expands its biosimilars capabilities with the acquisition of Dutch biotech Bioceros.
Deal Watch: Immuno-Oncology Collaborations Keep Piling Up
AstraZeneca and Genentech sign agreements with a number of firms with promising early stage assets, with Bristol looking to spread reach into rare cancers; J&J joins the game. Drama continues to unfold for Mylan/Perrigo, Shire/Baxalta and Horizon/Depomed.
Evotec CEO: Growth Prospects Rely Heavily On Roche, Sanofi Deals
After disappearance last year of its drug hope DiaPep277 due to fraud, Germany’s Evotec is now looking to its Alzheimer’s MAO partnership with Roche and newly entered R&D alliance with Sanofi for future growth.